Hep C Drug Stocks in the Spotlight

Description:

According to Adam Feuerstein, "Biotech and drug investors with interest in emerging treatments for hepatitis C turn their attention this week to the European Association for the Study of the Liver (EASL) annual meeting, which kicks off Weds. March 30." Read more here.

>>Also: Top-Rated Biotech Stocks

>>Also: 40 Stocks Analysts Are Insanely Bullish About

Most Viewed Portfolios

View All

Articles

5 Toxic Stocks You Need to Sell Now

08.29.14 | 12:32 PM

BALTIMORE (Stockpickr) -- The S&P 500 is quickly closing in on the double-digit gains mark this summer, up more that 8% year-to-date as I write. At...

5 Breakout Stocks Under $10 Set to Soar

08.28.14 | 02:41 PM

DELAFIELD, Wis. (Stockpickr) -- There isn't a day that goes by on Wall Street when certain stocks trading for under $10 a share don't experience m...

More Articles
blog comments powered by Disqus
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter